News headlines about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 43.9578600394011 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
KERX has been the subject of a number of research analyst reports. Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Morgan Stanley decreased their target price on Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, February 8th. ValuEngine cut Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 22nd. Finally, BidaskClub raised Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, February 24th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. Keryx Biopharmaceuticals currently has an average rating of “Hold” and a consensus price target of $7.19.
Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.17 during trading on Tuesday, reaching $4.79. The company’s stock had a trading volume of 447,108 shares, compared to its average volume of 1,232,213. Keryx Biopharmaceuticals has a 52 week low of $4.01 and a 52 week high of $8.38. The company has a quick ratio of 2.49, a current ratio of 3.12 and a debt-to-equity ratio of -8.87. The firm has a market cap of $593.49, a PE ratio of -3.33 and a beta of 2.60.
In other Keryx Biopharmaceuticals news, General Counsel Brian Adams sold 5,652 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total transaction of $27,186.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Greg Madison sold 15,318 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total value of $73,679.58. The disclosure for this sale can be found here. Insiders have sold a total of 43,182 shares of company stock valued at $208,175 over the last ninety days. 2.58% of the stock is owned by insiders.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.